Добірка наукової літератури з теми "Wu Ming 2"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Wu Ming 2".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Wu Ming 2"
1
Milanesi, Claudio. "Camminare, divagare, andare dritti alla metaJean-Jacques Rousseau, Sören Kierkegaard, Wu Ming 2 e me." Italies, no. 17/18 (October 1, 2014): 835–46. http://dx.doi.org/10.4000/italies.4994.
Повний текст джерела
2
Bingenheimer, Marcus. "Miyun Yuanwu 密雲圓悟 (1567–1642) and His Impact on 17th-Century Buddhism". Religions 14, № 2 (13 лютого 2023): 248. http://dx.doi.org/10.3390/rel14020248.
Повний текст джерелаАнотація:
This paper relies on the dataset “Historical Social Network of Chinese Buddhism” (Ver. 2021-06). The focus is on the period between c. 1570 and 1700 CE. We argue that the actor who was most influential for institutional Buddhism in the 17th century was not one of the “four great monks of the late Ming” but rather Miyun Yuanwu 密雲圓悟 (1566–1642). The network illustrates how Miyun’s Tiantong branch 天童派 of the Linji School became the dominant Chan lineage in China and beyond. The main results of this study are: (1) the data corroborate the assumption that (at least) monastic Buddhism declined between c. 1420 and 1570. (2) The network view de-emphasizes the importance of the ‘four famous late Ming eminent monks’ for the development of 17th-century Buddhist monasticism. (3) The data align well with a suggestion by Jiang Wu to distinguish two different stages in the development of late Ming Buddhism. The first is characterized by the “late Ming revival,” led by figures such as Yunqi Zhuhong, Zibo Zhenke, and Hanshan Deqing; the second phase is the organization of orthopraxy around the Chan lineage discourse dominated by Miyun Yuanwu and his students. (4) For the 17th century, the network data clearly shows the centrality of Miyun Yuanwu and his network.
3
Bertossa, Michela, Lawrence Gianangeli, and Luca Peretti e Enrico Zammarchi. "Timira, romanzo meticcio e stratificato." Forum Italicum: A Journal of Italian Studies 55, no. 1 (February 20, 2021): 68–84. http://dx.doi.org/10.1177/0014585820988509.
Повний текст джерелаАнотація:
L’articolo esamina il romanzo Timira, scritto da Antar Mohamed Marincola e Wu Ming 2 e pubblicato nel 2012. Ci concentriamo su due macrotemi: la marginalità spaziale e culturale rappresentata nel libro o percepita dai personaggi (la città, la periferia, la controcultura, e l’attivismo politico), e come razzismo, sessismo e colonialismo plasmino non solo l’identità della protagonista Isabella Marincola ma anche le sue esperienze nel mondo artistico e cinematografico. Il saggio è frutto di un esperimento di scrittura collettiva, nella convinzione che questa pratica dovrebbe essere più diffusa nelle scienze umane, e che un romanzo complesso e stratificato come Timira possa essere affrontato a più voci e da punti di vista diversi.
4
Qiu, Jane. "Great strides of China's space programmes." National Science Review 4, no. 2 (February 24, 2017): 264–68. http://dx.doi.org/10.1093/nsr/nwx006.
Повний текст джерелаАнотація:
Abstract While China's almost flawless space endeavours—such as its space lab Tiangong-2, launched last year, and the 2012 mission that sent a rover to the surface of the Moon—have long impressed the world, space-science missions were not among its priorities until recently. The situation improved in 2011 when the Chinese Academy of Sciences won government support for a 10-year Strategic Pioneering Programme on Space Science—with a total budget of nearly 1 billion dollars. Since then, China has launched satellites to probe dark matter, detect black holes and conduct quantum experiments from space. This year will see the launch of an astronomy satellite and a highly anticipated mission to bring back rocks from the Moon. In a forum chaired by National Science Review's Executive Associate Editor Mu-ming Poo, space scientists discussed different types of Chinese space programmes, the science missions already launched or in development, the importance and challenges of international collaboration, and the uncertain future of the country's space-science development. Chunlai Li Deputy Director, National Astronomical Observatories, Chinese Academy of Sciences, Beijing Ji Wu Director, National Centre of Space Science, Chinese Academy of Sciences, Beijing Jianyu Wang Deputy Director, Chinese Academy of Sciences Shanghai Branch Shuangnan Zhang Institute of High-Energy Physics, Chinese Academy of Sciences, Beijing Yifang Wang Director, Institute of High-Energy Physics, Chinese Academy of Sciences, Beijing Mu-ming Poo (Chair) Director, Institute of Neuroscience, Institute of High-Energy Physics, Chinese Academy of Sciences, Shanghai
5
Chen, Li, Yi-Zhou Jiang, Songyang Wu, Jiong Wu, Genhong Di, Guangyu Liu, Keda Yu, et al. "Abstract P2-14-04: Updated data from FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase 2 trial." Cancer Research 82, no. 4_Supplement (February 15, 2022): P2–14–04—P2–14–04. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-14-04.
Повний текст джерелаАнотація:
Abstract Background Camrelizumab and nab-paclitaxel demonstrated promising anti-tumour activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC) in FUTURE trial. Anti-angiogenic agents have been reported to facilitate immune infiltration. Famitinib is a tyrosine kinase inhibitor targeting VEGFR-2, PDGFR and c-kit. The FUTURE-C-PLUS trial (NCT04129996) which added famitinib to camrelizumab and nab-paclitaxel is a single-arm, phase 2 trial evaluating this novel triplet combinatorial strategy in patients with advanced immunomodulatory TNBC. Study design and the primary endpoint ORR has been reported previously (Zhi-ming Shao, et al. ASCO 2021, Abstract 1007). Here, we reported the updated results of this trial. Method Briefly, this study enrolled women aged 18-70 years, with previously untreated, histologically confirmed, unresectable, locally advanced, recurrent or metastatic immunomodulatory TNBC. Immunomodulatory TNBC was defined as CD8 expression on at least 10% of cells using immunohistochemistry analysis. Eligible patients received the triple therapy. Study design has been reported previously in ASCO 2021. Results Between Oct 2019 and Oct 2020, 48 patients were enrolled and treated. 39 (81.3%, 95% CI 70.2-92.3) patients had a confirmed objective response which has been reported in ASCO 2021. At this updating data cutoff (June 30, 2021), the median progression-free survival was 11.9 months (95% CI, 7.3-16.5) with the median follow-up was 14.0 months. While overall survival data were not mature yet, a promising overall survival rate was observed at 12 months (84•2%, 95% CI 73.4-95.0) and 18 months (73.6%, 95% CI 52.0-95.2). In the 39 responders, median duration of response was also not mature. The disease control rate was 95.8% (46/48). The most common treatment-related grade 3 or 4 adverse events were neutropenia (16 [33.3%]), anemia (5 [10.4%]), febrile neutropenia (5 [10.4%]), and thrombocytopenia (4 [8.3%]). No treatment-related deaths were reported. Conclusions These data, combined with those from our previous reports, provide further evidence for the triplet combination of famitinib, camrelizumab and nab-paclitaxel as an active therapy in advanced Immunomodulatory TNBC. To our knowledge, this is the best objective response rate reached in first-line treatment of advanced TNBC. A randomized controlled FUTURE-Super trial (NCT04395989) is keeping recruiting patients to further validate those findings. Citation Format: Li Chen, Yi-Zhou Jiang, Songyang Wu, Jiong Wu, Genhong Di, Guangyu Liu, Keda Yu, Lei Fan, Junjie Li, Yifeng Hou, Zhen Hu, Canming Chen, Xiaoyan Huang, Ayong Cao, Xin Hu, Shen Zhao, Xiaoyan Ma, Xiaoyu Zhu, Jianjun Zou, Wentao Yang, Zhonghua Wang, Zhi-ming Shao. Updated data from FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase 2 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-14-04.
6
Shao, Zhi-Ming, Zhong-Hua Wang, Yi-Zhou Jiang, Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, et al. "Abstract OT3-27-01: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial." Cancer Research 83, no. 5_Supplement (March 1, 2023): OT3–27–01—OT3–27–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-ot3-27-01.
Повний текст джерелаАнотація:
Abstract Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and lacks effective treatment. Our previous study classified TNBCs into four subtypes (luminal androgen receptor [LAR], immunomodulatory [IM], basal-like immune-suppressed [BLIS], mesenchymal-like [MES]) with distinct molecular features. We aimed to assess the efficacy and safety of molecular subtype-derived precision treatment in patients with heavily pretreated metastatic TNBC. Methods: This open-label, phase 2, umbrella trial included patients from four centers in China. Participants were women (aged ≥18 years) with histologically confirmed metastatic TNBC with disease progression after multiple lines of standard chemotherapy. Patients were enrolled into seven parallel arms according to their molecular subtypes: LAR with or without ERBB2 somatic mutation/amplification assigned to arm A (pyrotinib with capecitabine) and arm B (androgen inhibitor included therapy); IM assigned to arm C (anti-PD-1 antibody with nab-paclitaxel); BLIS with or without BRCA1/2 germline mutation assigned to arms D (PARP inhibitor included therapy) and E (anti-VEGFR included therapy); MES without or with PI3K-AKT mutation assigned to arms F (anti-VEGFR included therapy) and G (everolimus with nab-paclitaxel). Bayesian predictive probability was adopted to monitor each arm, which can be terminated independently according to a prespecified futility or efficacy boundary. This trial is registered with ClinicalTrials.gov, NCT03805399. Findings: Between October 18, 2018, and February 11, 2022, we enrolled 141 patients. All patients were heavily pretreated and resistant to six categories of the most common chemotherapeutic agents used in breast cancer treatment, with a median of 3 previous lines of therapies in the metastatic setting (Table 1 and 2). The median follow-up was 18.3 months (IQR 11.7-27.7). A confirmed objective response was achieved in 42 (29.8%, 95% CI 22.4-38.1) of the 141 patients. The median PFS was 3.4 months (95% CI 2.7-4.2), and the median OS was 10.7 months (95% CI 9.0-12.3) (Table 3). Arms A, C, E and G achieved efficacy boundaries, with 3 (75.0%) out of 4 patients in arm A, 20 (43.5%) out of 46 patients in arm C, 13 (28.3%) out of 46 patients in arm E, and 3 (33.3%) out of 9 patients in arm G achieving objective responses. Potential predictive biomarkers of efficacy in each arm were explored. Safety data were consistent with the known safety profiles of relevant drugs. Interpretation: We demonstrate the feasibility and clinical utility of a subtyping-based, genomic sequencing-guided strategy which allows the majority of heavily pretreated metastatic TNBCs to benefit from precision treatment. Most arms exhibit promising efficacy and manageable toxicities, providing subtyping schema to optimize personalized treatment. Table 1. The FUTURE trial schema. Patients are stratified into seven arms using the FUSCC 484-gene NGS panel testing and IHC subtyping. Abbreviations: mTNBC, metastatic triple-negative breast cancer; NGS, next-generation sequencing; IHC, immunohistochemistry; FUSCC, Fudan University Shanghai Cancer Center; LAR, luminal androgen receptor; IM, immunomodulatory; BLIS, basal-like immune-suppressed; MES, mesenchymal-like; n, number; AR, androgen receptor; PD-1, programmed cell death-1; PARPi, poly ADP-ribose polymerase inhibitor; VEGF, vascular endothelial growth factor; mTORi, mammalian target of rapamycin inhibitors. Table 2. Patient characteristics in the FUTURE trial. Table 3. Summary of treatment efficacy of TNBC in the FUTURE trial Citation Format: Zhi-Ming Shao, Zhong-Hua Wang, Yi-Zhou Jiang, Yin Liu, Xiu-Zhi Zhu, Yi Xiao, Song-Yang Wu, Wen-Jia Zuo, Qiang Yu, A-Yong Cao, Jun-Jie Li, Ke-Da Yu, Guang-Yu Liu, Jiong Wu, Tao Sun, Jiuwei Cui, Zheng Lv, Hui-Ping Li, Xiao-Yu Zhu. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT3-27-01.
7
Shi, JiaJie, Wei Li, Zhongsheng Tong, Aimin Zang, Xiaohua Zeng, Shui Wang, Tao Huang, et al. "Abstract P4-01-21: Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2– Advanced Breast Cancer." Cancer Research 83, no. 5_Supplement (March 1, 2023): P4–01–21—P4–01–21. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-01-21.
Повний текст джерелаАнотація:
Abstract Background: FCN-437c is a second-generation CDK4/6 inhibitor. Phase 1b clinical results indicated improved antitumor activity in patients (pts) with HR+, HER2– advanced breast cancer (ABC), treated with FCN-437c + letrozole. Methods: This Phase 2, multicenter, open-label clinical study evaluated the antitumor activity, pharmacokinetics (PK), and safety of FCN-437c + fulvestrant in post-menopausal pts (Cohort 1, treatment-naïve or 2L), FCN-437c + letrozole + goserelin in pre-menopausal pts (Cohort 2, treatment-naïve). Pts received FCN-437c (200 mg QD) in a 21-day-on and 7-day-off schedule either in combination with fulvestrant (500 mg D1) or letrozole (2.5 mg QD) + goserelin (3.6 mg once per cycle) in 28-day cycles. The primary endpoint was overall response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), PK, and safety. Results: At study cutoff (Feb 7, 2022), 36 pts were enrolled in Cohort 1 and 31 pts were in Cohort 2; 42 (62.7%) pts had visceral metastases and 9 (13.4%) pts had bone-only metastases. In Cohort 1, 18 pts were treatment-naïve, 15 pts had received 1L treatment, and 3 pts had received ≥2L treatment. In Cohort 2, 25 pts were treatment-naïve and 6 pts had received 1L treatment. Overall, 27 pts in the per-protocol set achieved partial response (PR), resulting in an ORR of 40.9% (95% CI, 29.0-53.7). Median follow-up was 12.8 months, and median PFS (mPFS), OS, and DOR were not reached. However, at 12 months, the PFS rate was 67.7% (95% CI, 53.2-78.6) and the OS rate was 95.9% (95% CI, 84.5-99.0); the 6-month DOR rate was 96.0% (95% CI, 74.8-99.4). In Cohort 1 (n=35), 11 pts achieved PR: the ORR was 31.4% (16.9-49.3%) and mPFS was 12.9 months (95% CI, 9.2-NR); the 6-month DOR rate was 100%. In Cohort 2 (n=31), 16 pts achieved PR: the ORR was 51.6% (95% CI, 33.1-69.9%). mPFS, OS, and DOR were not reached; the 6-month DOR rate was 92.9% (95% CI, 59.08-98.96) (Table). Treatment-emergent adverse events (TEAEs) were observed in all pts. Majority of AE were G1 or 2 except for hematological TEAE. 58 (86.6%) pts reported grade ≥3 TEAEs, mainly neutropenia (74.6%), leukopenia (49.3%), hypertriglyceridemia (6.0%), lymphocyte count decrease (4.5%), and γ-glutamyltransferase increase (3.0%): most were reversed through dose interruption and symptomatic therapy. Steady-state PK parameters were analyzed after 15-21 days of QD administration: Cohort 1: median Tmax was 3 h, geomean T1/2 was 44.6 h, geomean Cmax was 1650.7 ng/mL, and geomean AUC0-24h was 29,148.08 h*ng/mL; the geomean accumulation ratios of AUC0-24h and RCmax were 2.18 and 1.74, respectively, compared with first dose. Cohort 2: median Tmax was 4 h, geomean T1/2 was 35.7 h, geomean Cmax was 1314.34 ng/mL, and geomean AUC0-24h was 22,889.96 h*ng/mL; the geomean accumulation ratios of AUC0-24h and RCmax were 1.95 and 1.63, respectively, compared with first dose. Conclusion: FCN-437c in combination with fulvestrant or letrozole + goserelin demonstrates antitumor activity and safety and is well tolerated in pts with HR+, HER2– ABC. This combination therapy will be further investigated in 2 ongoing Phase 3 trials (NCT05438810 and NCT05439499). Clinical trial number: NCT05004142. Research Sponsor: Avanc Pharmaceutical Co., Ltd Table. Clinical outcomes for patients in the per-protocol set. Citation Format: JiaJie Shi, Wei Li, Zhongsheng Tong, Aimin Zang, Xiaohua Zeng, Shui Wang, Tao Huang, Ying Wang, Yanqiu Song, Lihua Kang, Zheng Lv, Yehui Shi, Hua Yang, Jing Wu, Yongmei Yin, Yan Liang, Jie Tan, Jie Ming, Yaping Yang, Simin Luo, Xiujuan Gui, Ai-Min Hui, Zhuli Wu, Ling Tian, Yuchen Yang, Lei Diao, Wenjing Zhang, Yongjiao Zhang, Yunjiang Liu. Phase 2 Study of the CDK4/6 Inhibitor FCN-437c in Combination With Fulvestrant or Letrozole and Goserelin in Patients With HR+, HER2– Advanced Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-01-21.
8
WU, SHIPHER, MAMORU OWADA, and CHIEN-MING FU. "SHIPHER WU, MAMORU OWADA & CHIEN-MING FU (2013) Rediscovery of two rare ptilodontines in Taiwan: Himeropteryx yui Okano, 1969 stat. nov. and Ptilophora rufula Kobayashi, 1994 (Lepidoptera, Notodontidae). Zootaxa, 3702 (2), 193–197." Zootaxa 3710, no. 2 (September 12, 2013): 200. http://dx.doi.org/10.11646/zootaxa.3710.2.7.
Повний текст джерела
9
Chen, Tom Wei-Wu, Wen Hsiao, Ming-Shen Dai, Ching-Hung Lin, Dwang-Ying Chang, I.-Chun Chen, Ming-Yang Wang, et al. "Abstract P2-01-09: Clinical impact of ESR1 mutation ctDNA on survival outcome is dependent on PI3KCA/TP53 ctDNA mutation status." Cancer Research 82, no. 4_Supplement (February 15, 2022): P2–01–09—P2–01–09. http://dx.doi.org/10.1158/1538-7445.sabcs21-p2-01-09.
Повний текст джерелаАнотація:
Abstract Background: With more endocrine therapies- (ET) based treatment (tx) available, genomic markers that could assist in the prediction of tx outcome is critical. The role of ctDNA mutations in ER+/HER2- metastatic breast cancer (MBC) after prior ET is based on retrospective study results. Methods: ER+/HER2- MBC patients (pts) starting ET-based salvage tx were eligible (NCT04212702). Cell-free DNA (cfDNA) was extracted from plasma before tx, and prepared for next-generation sequencing (NGS) analysis. The targeted NGS for ctDNA included regions of the ESR1 ligand-binding domain, PIK3CA hotspot mutations, and TP53 DNA-bonding domain mutations. 96% of the samples were sequenced at an average depths >10000x using the Ion Torrent platform. Progression-free survival (PFS) was defined from the start of the salvage tx to the date of progression. Results: From 2015/08 to 2020/05, a total of 163 pts treated with ET-based tx were prospectively enrolled. The median age was 60 (32-92). 13%, 15%, 48%, and 17% of pts received ET only, ET + CDK4/6 inhibitor, ET + everolimus, and ET + metronomic chemotherapy, respectively. Only 14 patients received fulvestrant as ET. The median level of recovered cfDNA was 38.5 ng (range 4.4-1935) and the level of cfDNA was significantly and inversely correlated with PFS (p = 0.0032). With mutation ctDNA ≥ 0.5% as a threshold for positive calling, 100 (61.3%), 41 (25.1%), and 25 (15.3) pts have at least one ESR1, PIK3CA, and TP53 mutation, respectively and 61 (37.4%) pts had >1 ESR1 mutation genotypes. The median PFS of the cohort (n=163) was 8.3 mos (95% CI 5.7 – 11.1 mos). PIK3CA mutation (MT) in ctDNA was associated with a worse outcome in all patients (HR 1.91, 95% CI 1.20 to 3.04, p = 0.0064) and the subgroups of ET + everolimus (HR 2.20, 95% CI 1.10 – 4.39, p = 0.025) and ET + metronomic chemotherapy (HR 5.34, 95% CI 1.63- 17.54, p = 0.006). The presence of TP53 MT ctDNA was also associated with worse PFS (HR 1.81, p = 0.043, n = 163) but also exerted a poor prognostic impact in pts with wild type (WT) PIK3CA (HR 3.28, 95% CI 1.44 – 7.48, p = 0.0048). However, the variant allelic frequency (VAF) of PIK3CA MT (p = 0.0421), but not TP53 MT (p = 0.7723), had a inverse linear correlation with PFS. Surprisingly, pts with ESR1 MT had a better PFS as compared to ESR1 WT pts (HR 0.68 95% CI 0.46 – 0.99, p = 0.049). However, if the threshold for. variant calling was raised to 2%, then ESR1 MT (n= 52, 31.9%) vs WT pts had similar PFS (median PFS 8.6 vs 7.8 mos, HR 0.92, 95% CI 0.62-1.37, p = 0.69), suggesting that defining different VAF threshold of MT ESR1 may have divergent PFS impact. How ERS1 MT ctDNA affected PFS was dependent on PIK3CA/TP53 status. When either PIK3CA or TP53 MT ctDNA was present, the ESR1 MT ctDNA did not have any impact on PFS, regardless of VAF. In pts with WT PIK3CA/TP53, pts with ESR1 MT ctDNA VAF 0.5 – 2.0% had a significant better PFS as compared with triple WT pts (HR 1.9, p = 0.0035). Conclusion: Using a 3-gene panel for ctDNA testing with MT ctDNA ≥ 0.5% as a threshold for positive calling in ER+/HER2- MBC pts treated with ET-based tx, the presence of PIK3CA and TP53 mut in ctDNA conferred a worse prognosis. The positive prognostic impact of ESR1 was only noticeable in pts with PIK3CA and TP53 WT ctDNA, and the presence of a low VAF ESR1 MT ctDNA, which may suggest an ER denpendency, was significantly correlated with a better outcome. Table 1.Median PFS of pts with and without PIK3CA, TP53 and ESR in ctDNAPopulation (n)Genotype(s)Median PFS (mos)Hazard Ratiop-valueAll (163)PIK3CA MT (41) vs. WT (122)(VAF ≥ 0.5%)5.4 vs. 10.31.910.0064TP53 MT (25) vs. WT (143)(VAF ≥ 0.5%)4.1 vs. 8.91.810.0439ESR1 MT vs. WT(VAF ≥ 0.5%)9.8 vs. 5.80.680.0493ET + everolimus (82)PIK3CA MT vs. WT(VAF ≥ 0.5%)2.8 vs. 5.92.200.0254PIK3CA and TP53 WT (106)WT vs ESR1 MT (VAF ≥ 0.5% - < 2%)6 vs 15.61.910.0035WT vs ESR1 MT (VAF ≥ 2%)6 vs 121.360.355 Citation Format: Tom Wei-Wu Chen, Wen Hsiao, Ming-Shen Dai, Ching-Hung Lin, Dwang-Ying Chang, I-Chun Chen, Ming-Yang Wang, Ling-Yi Huang, Shu-Han Chang, Shu-Min Huang, Ann-Lii Cheng, Kien Thiam Tan, Yen-Shen Lu. Clinical impact of ESR1 mutation ctDNA on survival outcome is dependent on PI3KCA/TP53 ctDNA mutation status [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-01-09.
10
Talwar, Harvinder S., Shiwesh Kumar, Ragimasalawada Madhusudhana, Ganapathy K. Nanaiah, Swarna Ronanki, and Vilas A. Tonapi. "Variations in drought tolerance components and their association with yield components in finger millet (Eleusine coracana)." Functional Plant Biology 47, no. 7 (2020): 659. http://dx.doi.org/10.1071/fp19274.
Повний текст джерелаАнотація:
Finger millet has gained considerable attention worldwide due to its nutritional and health benefits. Being a rainfed crop of semiarid and arid regions, drought is one of the major constraints to its yield stabilisation. To address this, a set of 38 accessions of finger millet were evaluated in both field and mini-lysimeters under both well-watered (WW) and water-stressed (WS) conditions. The objectives of the study were to identify the range of variations for yield components, water-use (WU) and transpiration efficiency (TE) and to examine the potential of the mini-lysimeter system in assessing the genotypic performance in the field conditions. Approximately 2-fold variations in shoot biomass and ~9-fold variations in grain yield under WS conditions were observed. Reproductive growth was more sensitive to WS than the vegetative growth. Our results indicate that in addition to yield potential under WW conditions, WU followed by TE were the other two major contributors toward shoot biomass, whereas, HI followed by TE were the major contributors toward grain yield under WS. The close association between the yield components recorded in the field and in mini-lysimeters suggests that the lysimetric system has the great potential to reflect the genotypic performance under field conditions. Regression analyses suggest that HI explained almost all the variations in grain yield under WW conditions, whereas under WS treatment, next to HI, both TE and WU had also contributed significantly to grain yield. The absence of interrelationship between WU and TE suggests that both these components contribute independently toward the yield components under WW or WS conditions. The accessions with higher shoot biomass and grain yield extract much more water during the post-anthesis stages than the poor performers under WS. Results also suggests that higher WU contributed more towards shoot biomass and higher TE contributed more towards grain yield by improving the harvest index.
Дисертації з теми "Wu Ming 2"
1
Mondillo, Mirko. "Dire (l’)io, dire il vero, dire nell’ipermoderno italiano. L’interazione tra scritture dell’esperienza personale e scrittura saggistica nel romanzo ego-saggistico. I casi di Rea, Siti e Wu Ming 2 e Antar Mohamed." Doctoral thesis, Università di Siena, 2022. http://hdl.handle.net/11365/1215894.
Повний текст джерелаАнотація:
This dissertation analyses Ermanno Rea’s Mistero napoletano (1995), Walter Siti’s Troppi paradisi (2006) and Wu Ming 2 & Antar Mohamed’s Timira. Romanzo meticcio (2012) as three case-studies of how writing connected to personal experiences and essayistic genres are combined in such a way as to give way to what can be defined as a first-person essay-novel. This literary form can also be considered as a typical example of what the literary scholar Raffaele Donnarumma has called “hypermodernity” in contemporary Italian literature, a multifaceted literary trend consisting in the critical and creative exploration of the possible interactions between literary forms and societal issues.
The expression “personal experience writing” is used for a broad variety of life-writing, ranging from “traditional” forms of autobiography, biography and diary entries to creative literary adaptations of these forms (autofiction, biofiction, narrative diary). The “essayistic writing” that has been addressed include a wide set of discursive and argumentative modules through which authors elaborate and reflect on the literary, cultural, political and social contexts with which they interact as creative writers.
Книги з теми "Wu Ming 2"
1
Luo, Fuman. Hui sa jiao de nü ren zui hao ming: Everyone tender woman 2. Guang zhou: Hua cheng chu ban she, 2009.
Знайти повний текст джерела
2
China. Quan guo ren min dai biao da hui. Chang wu wei yuan hui. Ban gong ting. mi shu yi ju., ed. Di jiu jie quan guo ren min dai biao da hui ji qi chang wu wei yuan hui hui yi da shi ji: 1998 nian 3 yue zhi 2003 nian 2 yue. Beijing: Zhongguo min zhu fa zhi chu ban she, 2003.
Знайти повний текст джерела
3
Chujiu, Renshen. Tian Ming Wu Jun - 2. Independently Published, 2018.
Знайти повний текст джерела
4
Shu bian wu shi nian: Ji nian Zhongguo ren min jie fang jun di si bing tuan jin jun Yunnan ji Yunnan jie fang wu shi zhou nian. [Kunming Shi]: Yunnan ren min chu ban she, 2000.
Знайти повний текст джерелаЧастини книг з теми "Wu Ming 2"
1
Brioni, Simone. "5 • Camminare." In Diaspore. Venice: Fondazione Università Ca’ Foscari, 2022. http://dx.doi.org/10.30687/978-88-6969-625-1/005.
Повний текст джерелаАнотація:
This chapter argues that Wu Ming 2’s Il sentiero luminoso (2016) and Giuliano Santoro’s Su due piedi. Camminando per un mese attraverso la Calabria (2012) describe walking as an activity which allows one to recognize the social modifications of space, and to rethink the geographies of suburban areas in Italy. This analysis resounds with Robert P. Marzec’s invitation to study how literature has represented the privatization and the capitalist and neoliberal organization of space, thus revealing forms of internal colonization, which epitomize a pillar of colonial ideology. Il sentiero luminoso and Su due piedi reconfigure walking as an epistemological, ecocritical and postcolonial practice which allows one to cross paths with people who are marginalized in Italy, especially migrants.
2
"III. »Bleiben ist nirgends. Restare è senza dove.«1 Stationen einer italosomalischen Odyssee: Timira von Wu Ming 2 und Antar Mohamed Marincola." In Postkoloniale Literatur in Italien, 93–128. transcript-Verlag, 2017. http://dx.doi.org/10.14361/9783839437735-003.
Повний текст джерела
3
"III. »Bleiben ist nirgends. Restare è senza dove.«1 Stationen einer italosomalischen Odyssee: Timira von Wu Ming 2 und Antar Mohamed Marincola." In Postkoloniale Literatur in Italien, 93–128. transcript Verlag, 2017. http://dx.doi.org/10.1515/9783839437735-003.
Повний текст джерела
4
Taber, Douglass F. "C–O Ring Construction: Sauropus Hexoside (Xie/Wu), (+)-Ipomeamarone (Usuki), Decytospolide A (Fujioka), Cytospolide P (Goswami), (+)-Didemniserinolipid B (Tong), Gymnothelignan N (She)." In Organic Synthesis. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190646165.003.0051.
Повний текст джерелаАнотація:
A range of biological activity was observed for the group of 3,6-anhydro-2-deoxy hexosides, of which 3 is representative, isolated from Sauropus rostratus. Wei-Jia Xie and Xiao-Ming Wu of China Pharmaceutical University prepared (Org. Lett. 2014, 16, 5004) 3 by the dealkylative cyclization of 1 to 2. (+)-Ipomeamarone 6 is a phytoalexin isolated from mold-damaged sweet potatoes. Yoshinosuke Usuki of Osaka City University assembled (Chem. Lett. 2014, 43, 1882) 6 by the diastereoselective cyclization of 4 to 5. Hiromichi Fujioka of Osaka University protected (Org. Lett. 2014, 16, 3680) the enone of 7 by the conjugate addition of triphenylphosphine. Diastereoselective reduction of the other ketone followed by deprotection of the enone and cyclization led to 8, that was hydrogenated to decytospolide A 9. En route to cytospolide P 12, Rajib Kumar Goswami of the Indian Association for the Cultivation of Science had planned (J. Org. Chem. 2014, 79, 7689) the ring-closing metathesis of 10. This failed, but cyclization of the corresponding silyl ether to 11 was successful with the second-generation Hoveyda catalyst. Rongbiao Tong of the Hong Kong University of Science and Technology set (J. Org. Chem. 2014, 79, 6987) the absolute configuration of (+)-didemniserinolipid B 15 by Sharpless asymmetric osmylation of the alkene 13. Oxidative Achmatowicz rearrangement/bicycloketalization then delivered 14. Xuegong She of Lanzhou University observed (Org. Lett. 2014, 16, 4440) remarkable diastereoselectivity in the reductive cyclization of 16 to 17. Oxidation of 17 led to regioselective cyclization to gymnothelignan N 18.
5
Taber, Douglass F. "Natural Product Synthesis by C–H Functionalization: (–)-Zampanolide (Ghosh), Muraymycin D2 (Ichikawa), (+)-Sundiversifolide (Iwabuchi), (+)-Przewalskin B (Zhang/Tu), Artemisinin (Wu)." In Organic Synthesis. Oxford University Press, 2015. http://dx.doi.org/10.1093/oso/9780190200794.003.0023.
Повний текст джерелаАнотація:
Arun K. Ghosh of Purdue University exposed (Org. Lett. 2011, 13, 4108) the ether 1 to DDQ. Hydride abstraction initiated nucleophilic addition of the allyl silane, which proceeded with high diastereocontrol to deliver 2, a key intermediate in the synthesis of (+)-zampanolide 3. Satoshi Ichikawa, after surveying (Org. Lett. 2011, 13, 4028) several N-protecting groups, settled on the phthalimide 4 as the best for directing the Du Bois oxidative cyclization. The sulfamate 5 was carried forward to a key component for the assembly of muraymycin D2 6. Yoshiharu Iwabuchi of Tohoku University found (Org. Lett. 2011, 13, 3620) that the silyl diazo ester 7 cyclized with high regiocontrol, inserting with retention of absolute configuration into the H adjacent to the ether oxygen. The insertion also proceeded with high diastereocontrol, to deliver an intermediate silyl lactone that was suitably arrayed for the subsequent Peterson elimination to give 8, a key intermediate for the synthesis of (+)-sundiversifolide 9. Fu-Ming Zhang and Yong-Qiang Tu of Lanzhou University prepared (J. Org. Chem. 2011, 76, 6918) the α-diazo β-keto ester 10. Rh-catalyzed intramolecular C–H insertion, again with retention of absolute configuration, gave an intermediate that on deprotection cyclized to the lactone 11, only a few steps removed from (+)-przewalskin B 12. Yikang Wu of the Shanghai Institute of Organic Chemistry devised (Org. Lett. 2011, 13, 4212) a novel preparation for cyclic peroxides such as 13. Gentle oxidation of 13 led to 14, which was further oxidized to artemisinin 15. Also known as qinghaosu, 15 is the key active component of current antimalarials.
6
"Appendix 2. Names and Reign Dates for the Rulers of Min, Wu, Southern Tang, and Wuyue." In Patrons and Patriarchs, 147–48. University of Hawaii Press, 2017. http://dx.doi.org/10.1515/9780824857240-013.
Повний текст джерела